On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnosis and treatment scheme for novel coronavirus pneumonia (Ninth Edition) through research. The details are as follows:

1、 Drug name:

Azivudine 

2、 Indications

It is used to treat adult patients with common novel coronavirus pneumonia (covid-19).

3、 Usage and dosage

Swallow the whole tablet on an empty stomach, 5mg each time, once a day, and the course of treatment is not more than 14 days.

4、 Precautions:

It is not recommended to use it during pregnancy and lactation. It should be used with caution in patients with moderate or severe liver and kidney function damage.

On July 25, the State Food and Drug Administration announced that the State Food and drug administration, in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, had conducted emergency review and approval, and conditionally approved the registration application of azvudine tablets of Henan Zhenzhen Biotechnology Co., Ltd. to increase the indications for the treatment of novel coronavirus pneumonia.